Clinical Trial Update: Interleukin-2 in Treating Patients With Metastatic Kidney Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating interleukin-2 for metastatic renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Interleukin-2 (interleukin-2)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Kidney Cancer | Phase 3 | Status: COMPLETED